Q2 2025 Moderna Inc Earnings Call Transcript
Key Points
- Moderna Inc (MRNA) secured three FDA approvals, including mNEXSPIKE, a next-generation COVID vaccine, and mRESVIA for high-risk individuals.
- The company reported a 35% reduction in combined costs of sales, R&D, and SG&A compared to the second quarter of 2024.
- Moderna Inc (MRNA) ended the quarter with $7.5 billion in cash and investments, maintaining a strong financial position.
- Positive Phase III efficacy data for their flu vaccine was announced, which supports the advancement of their flu and flu-COVID combination programs.
- The UK Court of Appeal upheld the validity of Moderna's EP'949 patent, which was found to be infringed by Pfizer and BioNTech.
- Moderna Inc (MRNA) reported a net loss of $825 million for the quarter, although this was an improvement from the previous year.
- Product sales declined by 38% compared to the second quarter of 2024, primarily due to lower COVID vaccine sales.
- The company announced a 10% workforce reduction to align costs with current business conditions.
- There was a $300 million reduction in the high end of their 2025 projected revenue range due to a timing shift of UK COVID shipments.
- Cost of sales represented 105% of net product sales this quarter, up from 62% in the prior year, driven by lower volume.
Good day, and thank you for standing by. Welcome to Moderna's second quarter 2025 conference call. (Operator Instructions) Please be advised today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Lavina Talukdar, Head of IR. Please go ahead.
Thank you, Kevin. Good morning, and good afternoon, everyone. Thank you for joining today's call to discuss Moderna's second quarter 2025 financial results and business update. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the Investors section of our website. On today's call are Stephane Bancel, our Chief Executive Officer; Stephen Hoge, our President; and Jamey Mock, our Chief Financial Officer.
Before we begin, please note that this conference call will include forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see slide 2 of the accompanying
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
